Literature DB >> 23660195

Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.

L E Dansie1, K Phommahaxay, A G Okusanya, J Uwadia, M Huang, S E Rotschafer, K A Razak, D W Ethell, I M Ethell.   

Abstract

Fragile X Syndrome (FXS) is the most common single-gene inherited form of intellectual disability with behaviors characteristic of autism. People with FXS display childhood seizures, hyperactivity, anxiety, developmental delay, attention deficits, and visual-spatial memory impairment, as well as a propensity for obsessive-compulsive disorder. Several of these aberrant behaviors and FXS-associated synaptic irregularities also occur in "fragile X mental retardation gene" knock-out (Fmr1 KO) mice. We previously reported that minocycline promotes the maturation of dendritic spines - postsynaptic sites for excitatory synapses - in the developing hippocampus of Fmr1 KO mice, which may underlie the beneficial effects of minocycline on anxiolytic behavior in young Fmr1 KO mice. In this study, we compared the effectiveness of minocycline treatment in young and adult Fmr1 KO mice, and determined the dependence of behavioral improvements on short-term versus long-term minocycline administration. We found that 4- and 8-week-long treatments significantly reduced locomotor activity in both young and adult Fmr1 KO mice. Some behavioral improvements persisted in young mice post-treatment, but in adults the beneficial effects were lost soon after minocycline treatment was stopped. We also show, for the first time, that minocycline treatment partially attenuates the number and severity of audiogenic seizures in Fmr1 KO mice. This report provides further evidence that minocycline treatment has immediate and long-lasting benefits on FXS-associated behaviors in the Fmr1 KO mouse model.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23660195      PMCID: PMC3813005          DOI: 10.1016/j.neuroscience.2013.04.058

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  72 in total

Review 1.  Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond.

Authors:  Aaron W Grossman; Georgina M Aldridge; Ivan Jeanne Weiler; William T Greenough
Journal:  J Neurosci       Date:  2006-07-05       Impact factor: 6.167

Review 2.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

Review 3.  Synaptic regulation of protein synthesis and the fragile X protein.

Authors:  W T Greenough; A Y Klintsova; S A Irwin; R Galvez; K E Bates; I J Weiler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures.

Authors:  Agustini Utari; Weerasak Chonchaiya; Susan M Rivera; Andrea Schneider; Randi J Hagerman; Sultana M H Faradz; Iryna M Ethell; Danh V Nguyen
Journal:  Am J Intellect Dev Disabil       Date:  2010-09

5.  Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences.

Authors:  V Võikar; A Polus; E Vasar; H Rauvala
Journal:  Genes Brain Behav       Date:  2005-06       Impact factor: 3.449

6.  Epilepsy and EEG findings in males with fragile X syndrome.

Authors:  S A Musumeci; R J Hagerman; R Ferri; P Bosco; B Dalla Bernardina; C A Tassinari; G B De Sarro; M Elia
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

7.  Minocycline-induced lupus: clinical features and response to rechallenge.

Authors:  T M Lawson; N Amos; D Bulgen; B D Williams
Journal:  Rheumatology (Oxford)       Date:  2001-03       Impact factor: 7.580

8.  GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism.

Authors:  Marjelo A Mines; Christopher J Yuskaitis; Margaret K King; Eleonore Beurel; Richard S Jope
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

9.  Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression.

Authors:  Jessica L Banko; Lingfei Hou; Francis Poulin; Nahum Sonenberg; Eric Klann
Journal:  J Neurosci       Date:  2006-02-22       Impact factor: 6.167

10.  Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1.

Authors:  Sean M Gallagher; Christine A Daly; Mark F Bear; Kimberly M Huber
Journal:  J Neurosci       Date:  2004-05-19       Impact factor: 6.167

View more
  42 in total

1.  Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome.

Authors:  Jonathan W Lovelace; Maham Rais; Arnold R Palacios; Xinghao S Shuai; Steven Bishay; Otilia Popa; Patricia S Pirbhoy; Devin K Binder; David L Nelson; Iryna M Ethell; Khaleel A Razak
Journal:  Cereb Cortex       Date:  2020-03-14       Impact factor: 5.357

2.  Abnormal development of auditory responses in the inferior colliculus of a mouse model of Fragile X Syndrome.

Authors:  Anna O Nguyen; Devin K Binder; Iryna M Ethell; Khaleel A Razak
Journal:  J Neurophysiol       Date:  2020-04-22       Impact factor: 2.714

3.  Degraded speech sound processing in a rat model of fragile X syndrome.

Authors:  Crystal T Engineer; Tracy M Centanni; Kwok W Im; Kimiya C Rahebi; Elizabeth P Buell; Michael P Kilgard
Journal:  Brain Res       Date:  2014-04-05       Impact factor: 3.252

4.  Developmental Changes in EEG Phenotypes in a Mouse Model of Fragile X Syndrome.

Authors:  Teresa H Wen; Jonathan W Lovelace; Iryna M Ethell; Devin K Binder; Khaleel A Razak
Journal:  Neuroscience       Date:  2018-12-05       Impact factor: 3.590

5.  Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9.

Authors:  Maximiliano A Toledo; Teresa H Wen; Devin K Binder; Iryna M Ethell; Khaleel A Razak
Journal:  Behav Brain Res       Date:  2019-07-02       Impact factor: 3.332

6.  Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome.

Authors:  Maria Isabel Carreno-Munoz; Fabienne Martins; Maria Carmen Medrano; Elisabetta Aloisi; Susanna Pietropaolo; Corentin Dechaud; Enejda Subashi; Guillaume Bony; Melanie Ginger; Abdelmalik Moujahid; Andreas Frick; Xavier Leinekugel
Journal:  Neuropsychopharmacology       Date:  2017-07-19       Impact factor: 7.853

Review 7.  Review of targeted treatments in fragile X syndrome.

Authors:  Andrew Ligsay; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2016-08

8.  Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.

Authors:  Harpreet Sidhu; Lorraine E Dansie; Peter W Hickmott; Douglas W Ethell; Iryna M Ethell
Journal:  J Neurosci       Date:  2014-07-23       Impact factor: 6.167

Review 9.  From FMRP function to potential therapies for fragile X syndrome.

Authors:  Ferzin Sethna; Changjong Moon; Hongbing Wang
Journal:  Neurochem Res       Date:  2013-12-18       Impact factor: 3.996

10.  Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome.

Authors:  Jonathan W Lovelace; Iryna M Ethell; Devin K Binder; Khaleel A Razak
Journal:  Neurobiol Dis       Date:  2018-03-29       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.